Your browser doesn't support javascript.
loading
Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer's disease.
Holstege, Henne; Hulsman, Marc; Charbonnier, Camille; Grenier-Boley, Benjamin; Quenez, Olivier; Grozeva, Detelina; van Rooij, Jeroen G J; Sims, Rebecca; Ahmad, Shahzad; Amin, Najaf; Norsworthy, Penny J; Dols-Icardo, Oriol; Hummerich, Holger; Kawalia, Amit; Amouyel, Philippe; Beecham, Gary W; Berr, Claudine; Bis, Joshua C; Boland, Anne; Bossù, Paola; Bouwman, Femke; Bras, Jose; Campion, Dominique; Cochran, J Nicholas; Daniele, Antonio; Dartigues, Jean-François; Debette, Stéphanie; Deleuze, Jean-François; Denning, Nicola; DeStefano, Anita L; Farrer, Lindsay A; Fernández, Maria Victoria; Fox, Nick C; Galimberti, Daniela; Genin, Emmanuelle; Gille, Johan J P; Le Guen, Yann; Guerreiro, Rita; Haines, Jonathan L; Holmes, Clive; Ikram, M Arfan; Ikram, M Kamran; Jansen, Iris E; Kraaij, Robert; Lathrop, Marc; Lemstra, Afina W; Lleó, Alberto; Luckcuck, Lauren; Mannens, Marcel M A M; Marshall, Rachel.
Afiliação
  • Holstege H; Genomics of Neurodegenerative Diseases and Aging, Human Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands. h.holstege@amsterdamumc.nl.
  • Hulsman M; Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands. h.holstege@amsterdamumc.nl.
  • Charbonnier C; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands. h.holstege@amsterdamumc.nl.
  • Grenier-Boley B; Delft Bioinformatics Lab, Delft University of Technology, Delft, the Netherlands. h.holstege@amsterdamumc.nl.
  • Quenez O; Genomics of Neurodegenerative Diseases and Aging, Human Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands. m.hulsman1@amsterdamumc.nl.
  • Grozeva D; Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands. m.hulsman1@amsterdamumc.nl.
  • van Rooij JGJ; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands. m.hulsman1@amsterdamumc.nl.
  • Sims R; Delft Bioinformatics Lab, Delft University of Technology, Delft, the Netherlands. m.hulsman1@amsterdamumc.nl.
  • Ahmad S; Université Rouen Normandie, INSERM U1245 and CHU Rouen, Department of Genetics and CNRMAJ, Rouen, France.
  • Amin N; Université Lille, INSERM, Centre Hospitalier Universitaire Lille, Institut Pasteur de Lille, U1167-RID-AGE facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Lille, France.
  • Norsworthy PJ; Université Rouen Normandie, INSERM U1245 and CHU Rouen, Department of Genetics and CNRMAJ, Rouen, France.
  • Dols-Icardo O; Medical Research Council Centre for Neuropsychiatric Genetics and Genomics,, Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.
  • Hummerich H; Department of Neurology, Erasmus Medical Centre, Rotterdam, the Netherlands.
  • Kawalia A; Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands.
  • Amouyel P; Medical Research Council Centre for Neuropsychiatric Genetics and Genomics,, Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.
  • Beecham GW; Department of Epidemiology, Erasmus Medical Centre, Rotterdam, the Netherlands.
  • Berr C; Leiden Academic Centre for Drug Research, Leiden, the Netherlands.
  • Bis JC; Department of Epidemiology, Erasmus Medical Centre, Rotterdam, the Netherlands.
  • Boland A; Nuffield Department of Population Health Oxford University, Oxford, UK.
  • Bossù P; Medical Research Council Prion Unit at University College London, University College London Institute of Prion Diseases, London, UK.
  • Bouwman F; Department of Neurology, II B Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Bras J; Biomedical Research Networking Center on Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.
  • Campion D; Medical Research Council Prion Unit at University College London, University College London Institute of Prion Diseases, London, UK.
  • Cochran JN; Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Daniele A; Université Lille, INSERM, Centre Hospitalier Universitaire Lille, Institut Pasteur de Lille, U1167-RID-AGE facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Lille, France.
  • Dartigues JF; The John P. Hussman Institute for Human Genomics, University of Miami, Miami, FL, USA.
  • Debette S; Université Montpellier, INSERM, Institute for Neurosciences of Montpellier, Montpellier, France.
  • Deleuze JF; Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Denning N; Université Paris-Saclay, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Centre National de Recherche en Génomique Humaine Evry, Gif-sur-Yvette, France.
  • DeStefano AL; Experimental Neuro-psychobiology Laboratory, Department of Clinical and Behavioral Neurology, Istituto di Ricovero e Cura a Carattere Scientifico Santa Lucia Foundation, Rome, Italy.
  • Farrer LA; Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.
  • Fernández MV; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands.
  • Fox NC; Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA.
  • Galimberti D; Division of Psychiatry and Behavioral Medicine, Michigan State University College of Human Medicine, Grand Rapids, MI, USA.
  • Genin E; Université Rouen Normandie, INSERM U1245 and CHU Rouen, Department of Genetics and CNRMAJ, Rouen, France.
  • Gille JJP; HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.
  • Le Guen Y; Department of Neuroscience, Catholic University of Sacred Heart, Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.
  • Guerreiro R; Université Bordeaux, INSERM, Bordeaux Population Health Research Center, Bordeaux, France.
  • Haines JL; Université Bordeaux, INSERM, Bordeaux Population Health Research Center, Bordeaux, France.
  • Holmes C; Department of Neurology, Bordeaux University Hospital, Bordeaux, France.
  • Ikram MA; Université Paris-Saclay, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Centre National de Recherche en Génomique Humaine Evry, Gif-sur-Yvette, France.
  • Ikram MK; UKDRI Cardiff, School of Medicine, Cardiff University, Cardiff, UK.
  • Jansen IE; Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
  • Kraaij R; Framingham Heart Study, Framingham, MA, USA.
  • Lathrop M; Department of Neurology, Boston University School of Medicine, Boston, MA, USA.
  • Lemstra AW; Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
  • Lleó A; Department of Neurology, Boston University School of Medicine, Boston, MA, USA.
  • Luckcuck L; Department of Epidemiology, Boston University, Boston, MA, USA.
  • Mannens MMAM; Department of Medicine (Biomedical Genetics), Boston University, Boston, MA, USA.
  • Marshall R; Neurogenomics and Informatics Center, Washington University School of Medicine, St Louis, MO, USA.
Nat Genet ; 54(12): 1786-1794, 2022 12.
Article em En | MEDLINE | ID: mdl-36411364
Alzheimer's disease (AD), the leading cause of dementia, has an estimated heritability of approximately 70%1. The genetic component of AD has been mainly assessed using genome-wide association studies, which do not capture the risk contributed by rare variants2. Here, we compared the gene-based burden of rare damaging variants in exome sequencing data from 32,558 individuals-16,036 AD cases and 16,522 controls. Next to variants in TREM2, SORL1 and ABCA7, we observed a significant association of rare, predicted damaging variants in ATP8B4 and ABCA1 with AD risk, and a suggestive signal in ADAM10. Additionally, the rare-variant burden in RIN3, CLU, ZCWPW1 and ACE highlighted these genes as potential drivers of respective AD-genome-wide association study loci. Variants associated with the strongest effect on AD risk, in particular loss-of-function variants, are enriched in early-onset AD cases. Our results provide additional evidence for a major role for amyloid-ß precursor protein processing, amyloid-ß aggregation, lipid metabolism and microglial function in AD.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenosina Trifosfatases / Exossomos / Doença de Alzheimer / Transportador 1 de Cassete de Ligação de ATP Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Nat Genet Assunto da revista: GENETICA MEDICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenosina Trifosfatases / Exossomos / Doença de Alzheimer / Transportador 1 de Cassete de Ligação de ATP Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Nat Genet Assunto da revista: GENETICA MEDICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda